KORU Medical Systems, Inc. (KRMD)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $160.49M
Last updated: Nov 17, 2026 at 11:04 AM ET
KORU Medical Systems, Inc. (KRMD) Earnings: Report Dates and Results
KORU Medical Systems (KRMD) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, KORU Medical Systems reported EPS of $0.02, above the -$0.02 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
KRMD has an expected report date of Mar 10, 2027.
KRMD Earnings Call
The latest KRMD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 31 quarters below that had an estimate, KRMD beat 19, missed 4 and matched 8. Revenue for the quarter ended Sep 30, 2026 was $11.57M, up 11.3% from $10.40M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.02 | -$0.02 | -$0.02 - -$0.02 | +200.00% | Beat | N/A | 2 | 0 up, 1 down | Nov 10, 2026 | $11.57M |
| Jun 30, 2026 | $0.01 | -$0.02 | N/A | +150.00% | Beat | 0.0% | 2 | 0 up, 0 down | Aug 5, 2026 | $12.05M |
| Mar 31, 2026 | -$0.02 | -$0.01 | -$0.01 - $0.00 | -100.00% | Miss | N/A | 2 | 0 up, 1 down | May 6, 2026 | $11.76M |
| Dec 31, 2025 | $0.01 | -$0.02 | -$0.02 - $0.00 | +155.56% | Beat | N/A | 4 | 0 up, 0 down | Mar 12, 2026 | $10.90M |
| Sep 30, 2025 | -$0.02 | -$0.02 | -$0.03 - -$0.02 | +16.00% | Beat | N/A | 4 | 0 up, 1 down | Nov 12, 2025 | $10.40M |
| Jun 30, 2025 | $0.01 | -$0.02 | -$0.03 - -$0.01 | +150.00% | Beat | N/A | 4 | 1 up, 0 down | Aug 6, 2025 | $10.19M |
| Mar 31, 2025 | -$0.03 | -$0.03 | -$0.03 - -$0.02 | 0.00% | In line | N/A | 4 | 1 up, 1 down | May 7, 2025 | $9.64M |
| Dec 31, 2024 | -$0.03 | -$0.03 | -$0.03 - -$0.01 | 0.00% | In line | N/A | 3 | 2 up, 0 down | Mar 12, 2025 | $8.84M |
| Sep 30, 2024 | -$0.01 | -$0.04 | -$0.05 - -$0.03 | +75.00% | Beat | N/A | 5 | 0 up, 0 down | Nov 13, 2024 | $8.18M |
| Jun 30, 2024 | -$0.01 | -$0.04 | -$0.05 - -$0.04 | +75.00% | Beat | N/A | 5 | 0 up, 0 down | Aug 7, 2024 | $8.43M |
| Mar 31, 2024 | -$0.02 | -$0.04 | -$0.05 - -$0.03 | +50.00% | Beat | N/A | 5 | 0 up, 0 down | May 1, 2024 | $8.20M |
| Dec 31, 2023 | -$0.03 | -$0.04 | -$0.06 - -$0.02 | +25.00% | Beat | N/A | 5 | 0 up, 0 down | Mar 13, 2024 | $7.19M |
| Sep 30, 2023 | -$0.03 | -$0.05 | -$0.06 - -$0.03 | +40.00% | Beat | N/A | 5 | 0 up, 0 down | Nov 8, 2023 | $7.00M |
| Jun 30, 2023 | -$0.05 | -$0.06 | -$0.06 - -$0.05 | +16.67% | Beat | N/A | 3 | 0 up, 1 down | Aug 9, 2023 | $6.94M |
| Mar 31, 2023 | -$0.05 | -$0.05 | -$0.06 - -$0.04 | 0.00% | In line | N/A | 3 | 1 up, 0 down | May 4, 2023 | $7.39M |
| Dec 31, 2022 | -$0.04 | -$0.06 | -$0.06 - -$0.05 | +33.33% | Beat | N/A | 3 | 0 up, 0 down | Mar 8, 2023 | $7.34M |
| Sep 30, 2022 | -$0.03 | -$0.05 | -$0.06 - -$0.05 | +40.00% | Beat | N/A | 3 | 0 up, 0 down | Nov 9, 2022 | $7.76M |
| Jun 30, 2022 | -$0.06 | -$0.06 | -$0.08 - -$0.06 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Aug 3, 2022 | $6.55M |
| Mar 31, 2022 | -$0.05 | -$0.06 | -$0.06 - -$0.05 | +16.67% | Beat | N/A | 3 | 0 up, 0 down | May 4, 2022 | $6.24M |
| Dec 31, 2021 | -$0.02 | -$0.03 | -$0.05 - -$0.02 | +33.33% | Beat | N/A | 3 | 0 up, 0 down | Mar 2, 2022 | $6.49M |
| Sep 30, 2021 | -$0.02 | -$0.02 | -$0.03 - -$0.01 | 0.00% | In line | -300.0% | 3 | N/A | Nov 10, 2021 | $6.04M |
| Jun 30, 2021 | -$0.02 | -$0.02 | -$0.03 - -$0.01 | 0.00% | In line | -166.7% | 3 | N/A | Aug 11, 2021 | $5.53M |
| Mar 31, 2021 | -$0.03 | -$0.01 | -$0.01 - $0.00 | -200.00% | Miss | -400.0% | 3 | N/A | May 12, 2021 | $5.43M |
| Dec 31, 2020 | -$0.02 | -$0.01 | -$0.02 - $0.01 | -100.00% | Miss | -300.0% | 3 | N/A | Mar 23, 2021 | $4.06M |
| Sep 30, 2020 | $0.01 | $0.02 | $0.02 - $0.02 | -50.00% | Miss | -75.0% | 4 | N/A | Nov 3, 2020 | $6.08M |
| Jun 30, 2020 | $0.03 | $0.02 | $0.02 - $0.02 | +50.00% | Beat | 0.0% | 3 | N/A | Aug 4, 2020 | $7.71M |
| Mar 31, 2020 | $0.01 | $0.01 | $0.01 - $0.01 | 0.00% | In line | -50.0% | 1 | N/A | May 4, 2020 | $6.33M |
| Dec 31, 2019 | $0.01 | $0.01 | N/A | 0.00% | In line | -66.7% | N/A | N/A | Feb 25, 2020 | $6.22M |
| Sep 30, 2019 | $0.04 | $0.01 | N/A | +300.00% | Beat | +300.0% | 2 | N/A | Nov 5, 2019 | $6.62M |
| Jun 30, 2019 | $0.03 | $0.02 | N/A | +50.00% | Beat | +200.0% | N/A | N/A | Aug 6, 2019 | $5.35M |
| Mar 31, 2019 | $0.02 | $0.01 | N/A | +100.00% | Beat | +100.0% | N/A | N/A | Apr 30, 2019 | $4.97M |
| Dec 31, 2018 | $0.03 | N/A | N/A | N/A | N/A | +316.7% | N/A | N/A | Feb 12, 2019 | $4.27M |
| Sep 30, 2018 | $0.01 | N/A | N/A | N/A | N/A | +42.9% | N/A | N/A | Oct 23, 2018 | $4.55M |
| Jun 30, 2018 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 6, 2018 | $4.50M |
| Mar 31, 2018 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 7, 2018 | $4.03M |
| Dec 31, 2017 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 13, 2018 | $4.66M |
| Sep 30, 2017 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2017 | $3.85M |
| Jun 30, 2016 | $0.00 | N/A | N/A | N/A | N/A | -125.0% | N/A | N/A | Aug 30, 2016 | $2.99M |
| Mar 31, 2016 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 30, 2016 | $2.99M |
| Dec 31, 2015 | $0.01 | N/A | N/A | N/A | N/A | +15.2% | N/A | N/A | Feb 29, 2016 | $3.14M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.03, after -$0.07 the year before. It was $0.02 for the year ended Dec 31, 2015, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.03 | N/A |
| Dec 31, 2024 | -$0.07 | N/A |
| Dec 31, 2023 | -$0.16 | N/A |
| Dec 31, 2022 | -$0.18 | N/A |
| Dec 31, 2021 | -$0.09 | -400.0% |
| Dec 31, 2020 | $0.03 | -70.0% |
| Dec 31, 2019 | $0.10 | N/A |
| Dec 31, 2018 | $0.06 | +916.9% |
| Dec 31, 2017 | $0.01 | N/A |
| Dec 31, 2015 | $0.02 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,900 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,858 | 8 | |
| 2026Q2 | Jun 30, 2026 | 5,391 | 8 | |
| 2026Q1 | Mar 31, 2026 | 6,046 | 9 | |
| 2025Q4 | Dec 31, 2025 | 6,484 | 9 | |
| 2025Q3 | Sep 30, 2025 | 5,723 | 8 | |
| 2025Q2 | Jun 30, 2025 | 5,738 | 9 | |
| 2025Q1 | Mar 31, 2025 | 6,885 | 9 | |
| 2024Q4 | Dec 31, 2024 | 6,794 | 9 |
2026Q3 Earnings Call
Opening remarks
Louisa Smith Investor Relations Thank you, operator, and good afternoon, everyone. Joining me on the call today are Adam Kalbermatten, President and Chief Executive Officer of KORU Medical Systems, and Tom Adams, Chief Financial Officer. Earlier today, KORU released financial results for the third quarter ended September 30, 2026. A copy of the press release is available on the company's website. I encourage listeners to have our press release in front of them, which includes our financial results and commentary on the quarter. Additionally, we will use slides to support further commentary in today's call, which are also available on the Investor Relations section of our website. During this call, we will make certain forward-looking statements regarding our business plans and other matters. These comments are based on our predictions and expectations as of today. Actual events or results could differ materially due to risks and uncertainties, including those mentioned in the associated press release and our most recent filings with the SEC. We assume no obligation to update any forward-looking statements. During the call, management will also discuss certain non-GAAP financial measures. You'll find additional disclosures, including reconciliations of these non-GAAP measures with comparable GAAP measures in our press release, the accompanying investor presentation, and SEC filings. For the benefit of those listening to the replay, this call was held and recorded on Tuesday, November 10, 2026, at approximately 4:30 p.m. Eastern Time. Since then, the company may have made additional comments related to the topics discussed. I'd now like to turn the call over to Adam Kalbermatten, CEO. Adam, please go ahead.
Adam Kalbermatten CEO Thank you, Louisa, and good afternoon, everyone. I'll first begin with commentary on this quarter's business highlights before handing the call over to Tom to discuss financial results and our updated guidance. Before diving into the results, I want to make several points. KORU has an incredible opportunity ahead of it, and we are working hard to capture it. I don't want to get ahead of ourselves, but I'd like to note the following. First, we are executing on the core business. As we guided in our Q2 call, our top-line growth slowed in Q3, and we are on track to deliver high teens growth in Q4. We continue to grow our recurrent patient base ahead of the market and have made business profitability improvements, and we are pleased with the results. New initiatives take time, and we are working on some big things that could significantly expand our patient base. We are progressing the business along multiple strategic dimensions, opening new geographies, getting new drugs on label, addressing new indications, and adding new technologies. If we execute on these strategic priorities, the business will inflect.
Frequently Asked Questions About KRMD
When is KORU Medical Systems's next earnings date?
KORU Medical Systems's next earnings report is expected for Mar 10, 2027.
Did KRMD beat earnings estimates last quarter?
Yes. KORU Medical Systems reported EPS of $0.02 for the quarter ended Sep 30, 2026, above the -$0.02 estimate, a 200.00% surprise.
What EPS do analysts expect from KRMD next quarter?
The consensus EPS estimate for KORU Medical Systems for the quarter ending Dec 31, 2026 is -$0.01 from 6 analysts, with estimates from -$0.01 to $0.00.
How often does KRMD beat earnings estimates?
KORU Medical Systems beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +71.44%.
KRMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors